Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's ...

The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss ...

Merck (MRK) stock gains as company enters a global licensing deal with Hansoh Pharma to develop an oral obesity drug. Read ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...

Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...

On December 10, JD Health, in collaboration with Merck, a globally renowned biopharmaceutical leader, began offering ...